Lupin’s arm inks agreement to acquire branded product portfolio from Shionogi in Japan

02 Aug 2016 Evaluate

Lupin’s Japanese subsidiary - Kyowa Pharmaceutical Industry Company, has entered into a strategic asset purchase agreement with Shionogi & Company to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing authorization of the products to Kyowa.

As a part of this growth strategy, Shionogi would transfer 21 long-listed products to Kyowa, the Japanese subsidiary of Lupin. Kyowa is amongst the top 10 Generic companies in Japan and a market leader in Central Nervous System (CNS) space well known for its ‘AMEL’ brand, in addition to other generic pharmaceutical products in its portfolio. With this acquisition, Kyowa will rank sixth amongst generic companies in Japan.

The 21 products cover therapy areas such as Central Nervous System (CNS), Oncology, Cardiovascular and Antiinfectives. These 21 products had sales of JPY 9,400 million ($90 million) collectively on National Health Insurance (NHI) price basis.   


Lupin Share Price

2181.45 -9.05 (-0.41%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×